Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methenamine is a small molecule urinary tract antiseptic and antibacterial drug primarily used for the prophylaxis and long-term treatment of frequently recurring urinary tract infections (UTIs)[1][2][3][4]. It is administered orally as either the hippurate or mandelate salt. Methenamine itself has no direct antibacterial activity in alkaline environments; its mechanism of action relies on hydrolysis in acidic urine (pH <6), where it decomposes to release formaldehyde—a highly bactericidal agent that denatures bacterial proteins and nucleic acids[1][5][6][8]. The acid salt component (e.g., hippuric acid) helps maintain an acidic urine environment to optimize this effect. Methenamine is effective against a broad range of urinary pathogens but may be less effective against urea-splitting bacteria such as Proteus or Pseudomonas species that can alkalinize urine[6]. Microbial resistance to formaldehyde does not develop. Methenamine is approved for use in both adults and children for prevention and treatment of UTIs requiring long-term therapy[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methenamine.